Literature DB >> 9018054

Genetic analysis of the hepatitis C virus (HCV) genome from HCV-infected human T cells.

K Sugiyama1, N Kato, T Mizutani, M Ikeda, T Tanaka, K Shimotohno.   

Abstract

We recently established a cell culture system for the replication of hepatitis C virus (HCV) by using a human T cell leukaemia virus type I-infected cell line, MT-2, and showed that the quasi-species of the hypervariable region 1 observed in the original inoculum became homogeneous in MT-2 cells 10 days after inoculation of HCV. In this study, we obtained HCV cDNA clones covering the whole viral genome by RT-nested PCR using RNA from HCV-infected cloned MT-2C cells, which support viral replication more efficiently, at 12 days after inoculation. A total of 41 distinct HCV cDNA clones covering almost the whole viral genome were also isolated from a cDNA library derived from the original inoculum. Molecular evolutional analyses comparing the sequences of the HCV clones obtained from both sources revealed that the HCV populations became homogeneous in more than half of the compared regions. This finding suggests that limited HCV populations are able to replicate in MT-2C cells. In addition, we isolated cDNA clones containing a 3' X-tail sequence, which was recently identified as a bona fide 3' terminus of the HCV genome, in the HCV-infected MT-2C cells and confirmed that the nucleotide sequence of the 3' X-tail was highly conserved, suggesting its implication in HCV replication. Finally, on the basis of the sequences of HCV cDNA clones obtained from HCV-infected MT-2C cells, we determined the entire nucleotide sequence of the HCV genome containing the 3' X-tail as a candidate for an infectious HCV molecular clone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018054     DOI: 10.1099/0022-1317-78-2-329

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Full-genome nucleotide sequence of a hepatitis C virus variant (isolate name VAT96) representing a new subtype within the genotype 2 (arbitrarily 2k).

Authors:  E I Samokhvalov; M Hijikata; R I Gylka; D K Lvov; S Mishiro
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

3.  Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X.

Authors:  K Tsuchihara; T Tanaka; M Hijikata; S Kuge; H Toyoda; A Nomoto; N Yamamoto; K Shimotohno
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Authors:  Jin-Won Youn; Su-Hyung Park; Jae Ho Cho; Young Chul Sung
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Genetic analysis of hepatitis C virus with defective genome and its infectivity in vitro.

Authors:  Kazuo Sugiyama; Kenji Suzuki; Takahide Nakazawa; Kenji Funami; Takayuki Hishiki; Kazuya Ogawa; Satoru Saito; Kumiko W Shimotohno; Takeshi Suzuki; Yuko Shimizu; Reiri Tobita; Makoto Hijikata; Hiroshi Takaku; Kunitada Shimotohno
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

6.  Mutations in hepatitis C virus RNAs conferring cell culture adaptation.

Authors:  V Lohmann; F Körner; A Dobierzewska; R Bartenschlager
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Transgenic mouse expressing a full-length hepatitis C virus cDNA.

Authors:  J Matsuda; M Suzuki; C Nozaki; N Shinya; K Tashiro; K Mizuno; Y Uchinuno; K Yamamura
Journal:  Jpn J Cancer Res       Date:  1998-02

8.  Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon.

Authors:  Tetsuro Shimakami; Makoto Hijikata; Hong Luo; Yuan Yuan Ma; Shuichi Kaneko; Kunitada Shimotohno; Seishi Murakami
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.